PARIS, May 26, 2010 /PRNewswire/ — InspireMD,
Ltd. announced today the next generation MGuard stent, MGuard
Prime(R), a net protective Cobalt Chromium stent system. MGuard
Prime(R) offers an advanced patented Cobalt Chromium design,
superior flexibility and excellent deliverability on top of the
established benefits of the MGuard MicroNet(R) technology.
MGuard(TM) is now available with an improved delivery system.
Recently InspireMD introduced MGuard with a new improved delivery
system in selected regions. The new delivery system offers a state
of the art design and a superior deliverability. “We are very
pleased with the flexibility and performance of the new delivery
system. In our testing we have experienced a 15% improvement in
crossing profile and 45% improvement in pushability resistance.
These improvements will directly benefit Acute MI patients
throughout the world,” said Eli Bar,
CTO and VP R&D of InspireMD.
InspireMD will hold an Evening Symposium at the PCR this evening
at 6:30-8:00pm at the Concorde
Lafayette Hotel in Paris. The
symposium “MGuard – 2 Years Experience in Acute MI” will be chaired
by Dr. Martin B. Leon.
MGuard final adjudicated results of the MAGICAL trial, including
the long awaited 6 months clinical FU results, will be presented
for the first time at the EuroPCR. The MAGICAL Trial is a 60
patients STEMI study. Acute results as well as interim 30 day
clinical results have previously been presented by Dr. Dariusz Dukek, the study’s primary
investigator.
Also coming up at the EuroPCR, presented for the first time, the
final adjudicated results
‘/>”/>
